We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
Read MoreHide Full Article
On Sep 1, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) , a Braintree, MA-based leading provider of blood management solutions to customers encompassing blood and plasma collectors, plus hospitals and health care providers globally. The stock currently carries a Zacks Rank #3 (Hold).
Haemonetics has been trading above the broader industry since last month. The stock has till now gained 1.6% as against the broader industry’s 1.6% fall. The year-over-year increase in reported sales and gross margin buoys optimism.
Market is upbeat about Haemonetics’ encouraging growth in both Plasma and Haemonetics Management franchises. The company swung to operating income in first-quarter fiscal 2018 from losses in the year-ago quarter.
Haemonetics has been witnessing a strong flourish in Plasma franchise for quite some time now. Management has also maintained high confidence in the continued growth of its commercial plasma collection business. In the quarter, North America Plasma disposables revenues increased 6%. Growth continued to be led by a strong end-market demand for plasma-derived biopharmaceuticals.
The company’s Hospital business is also progressing well with the TEG line of products gaining popularity worldwide. The TEG 5000 is sanctioned for a broad set of indications in all top markets. The TEG 6s and TEG Manager’s approval are for the same set of indications across Europe, Australia and Japan.
On the flip side, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Management also doesn’t expect any early recovery in the Blood Center’s outcomes.
Macroeconomic uncertainty continues to pose a challenge for Haemonetics. Management also anticipates slower-than-expected product adoption by customers which might reduce revenues and profits. Also, currency fluctuations and a stiff competition continue to hamper the stock.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 21.6% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.9% over the last six months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
On Sep 1, we issued an updated research report on Haemonetics Corporation (HAE - Free Report) , a Braintree, MA-based leading provider of blood management solutions to customers encompassing blood and plasma collectors, plus hospitals and health care providers globally. The stock currently carries a Zacks Rank #3 (Hold).
Haemonetics has been trading above the broader industry since last month. The stock has till now gained 1.6% as against the broader industry’s 1.6% fall. The year-over-year increase in reported sales and gross margin buoys optimism.
Haemonetics Corporation Price and Consensus
Haemonetics Corporation Price and Consensus | Haemonetics Corporation Quote
Market is upbeat about Haemonetics’ encouraging growth in both Plasma and Haemonetics Management franchises. The company swung to operating income in first-quarter fiscal 2018 from losses in the year-ago quarter.
Haemonetics has been witnessing a strong flourish in Plasma franchise for quite some time now. Management has also maintained high confidence in the continued growth of its commercial plasma collection business. In the quarter, North America Plasma disposables revenues increased 6%. Growth continued to be led by a strong end-market demand for plasma-derived biopharmaceuticals.
The company’s Hospital business is also progressing well with the TEG line of products gaining popularity worldwide. The TEG 5000 is sanctioned for a broad set of indications in all top markets. The TEG 6s and TEG Manager’s approval are for the same set of indications across Europe, Australia and Japan.
On the flip side, the company has been witnessing sluggish revenue growth at the Blood Center franchise, significantly affecting its results over the past few quarters. Management also doesn’t expect any early recovery in the Blood Center’s outcomes.
Macroeconomic uncertainty continues to pose a challenge for Haemonetics. Management also anticipates slower-than-expected product adoption by customers which might reduce revenues and profits. Also, currency fluctuations and a stiff competition continue to hamper the stock.
Other Key Picks
A few better-ranked medical stocks are Edwards Lifesciences Corporation (EW - Free Report) , Lantheus Holdings, Inc. (LNTH - Free Report) and IDEXX Laboratories, Inc. (IDXX - Free Report) . Edwards Lifesciences sports a Zacks Rank #1 (Strong Buy), while Lantheus Holdings and IDEXX Laboratories carry a Zacks Rank #2 (Buy). You cansee the complete list of today’s Zacks #1 Rank stocks here.
Edwards Lifesciences has a long-term expected earnings growth rate of 15.2%. The stock has rallied roughly 19.8% over the last six months.
Lantheus Holdings has a long-term expected earnings growth rate of 12.5%. The stock has surged 21.6% over the last six months.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.8%. The stock has gained around 2.9% over the last six months.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>